Dementia and Alzheimer Disease

Despite a small cohort sample size, treated patients with E2814 demonstrated significant reductions in p-tau217 after 12 weeks of treatment, sustained through the 108-week time point.

Semaglutide was associated with a lower risk of Alzheimer diagnosis compared to other diabetes medications, especially in older adults and women.

Without a specific tailored Long COVID therapy, individualized treatment based on patient phenotypes, along with extensive evaluations, is essential for effective symptom management.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 25, 2024.

With the positive recommendation, it marks a key step toward eplontersen’s availability in Europe as a treatment for ATTR polyneuropathy.

In our latest roundtable series, experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline.

Neal K. Shah, chief executive officer at CareYaya Health Technologies, talked about Medicare making big moves in neurological care.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 18, 2024.

In our latest roundtable series, experts discussed Long COVID prevalence, underreporting, accurate diagnosis, and emphasized that Long COVID serves as an umbrella term.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 11, 2024.

The director of the Helen and Robert Appel Alzheimer’s Disease Research Institute at Weill Cornell Medicine talked about findings from a recently published study on immune responses to Alzheimer disease risk genes between male and female mice. [WATCH TIME: 4 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of September 2024, compiled all into one place by the NeurologyLive® team.

Erik Musiek, MD, PhD, a professor of neurology at Washington University in St. Louis, provided clinical insight on a presentation from ANA 2024 highlighting the intricate relationship between circadian rhythms, glial activation, and neuroinflammation in Alzheimer disease.

A group of experts from The Neuron Clinic shared their experience developing a novel inclusive clinical program to treat patients with early Alzheimer disease using lecanemab.

The disease area stronghold leader in neurodegeneration at Johnson & Johnson discussed data presented at AAIC 2024 highlighting different subtypes of Alzheimer disease that may lead to more personalized treatments. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 27, 2024.

A pair of neurologists from the University of California, Irvine, detailed some of the training and career focuses of large federal agencies in effort to address the shortage of neurologists. [WATCH TIME: 4 minutes]

Neal K. Shah, CEO of CareYaya Health Technologies, discussed a miniaturized brain-machine interface developed that could restore communication for patients with neurological disorders by translating brain activity into text.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 20, 2024.

Neal K. Shah, CEO of CareYaya Health Technologies, discussed how Apple's new health features could potentially be a game-changer for neurological health.

A pair of neurologists from the University of California, Irvine, provided commentary on the ways to help young investigators find their footing in research settings, and exposing them to opportunities major governmental agencies can provide. [WATCH TIME: 4 minutes]

The general neurologist at Brigham and Women’s Hospital described the approach and mindset in teaching neurology as the field continuously evolves. [WATCH TIME: 3 minutes]

At the 2024 AUPN Annual Meeting, a pair of neurologists provided perspectives on the attributes and ethics that make a great educator, stressing passion, intellectual humility, and inclusivity, among others. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending September 14, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 13, 2024.

The disease area stronghold leader in neurodegeneration at Johnson & Johnson provided insight on the importance of the Global Neurodegeneration Proteomics Consortium, illustrated in several presentations at the recently concluded AAIC 2024. [WATCH TIME: 7 minutes]

Michael McDermott, MD, chief medical executive of Baptist Health Miami Neuroscience Institute, provided commentary on the early stages of a recently designed protective surfing helmet.

Recent data and conversations with experts highlighted the increasing concern of Long COVID’s impact on the brain in patients who have been previously infected with the virus.

Catch up on any of the neurology news headlines you may have missed over the course of August 2024, compiled all into one place by the NeurologyLive® team.

VES001 demonstrated safety, strong target engagement, and normalization of progranulin levels in healthy volunteers, advancing toward a phase 2a trial.